Avoro Capital Advisors LLC
Q4 2020 13F-HR Holdings
Net value change ($000)
-1,231,908
(-17.5%)
New positions
8
Sold out positions
11
Turnover %
60.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| UTHR | 432,602 | NEW |
| Mirati Therapeutics, Inc. | 274,912 | 38.1% |
| ACAD | 104,247 | NEW |
| ARENA PHARMACEUTICALS INC | 90,069 | 38.8% |
| PMVP | 72,958 | 126.7% |
| PRAX | 68,709 | NEW |
| Horizon Therapeutics Public Ltd Co | 64,098 | 10.8% |
| SRPT | 63,138 | 26.8% |
| KURA | 56,032 | 75.1% |
| FOLD | 54,608 | 35.6% |
Top Reduces (Value $000, Stocks/ETFs)
| IMMUNOMEDICS INC | -2,232,038 | -100.0% |
| MyoKardia, Inc. | -256,982 | -100.0% |
| KPTI | -87,600 | -100.0% |
| ADAPY | -68,645 | -78.2% |
| QURE | -64,453 | -100.0% |
| MARINUS PHARMACEUTICALS, INC. | -38,550 | -100.0% |
| Athenex, Inc. | -35,387 | -89.6% |
| ALT | -26,400 | -100.0% |
| TVTX | -24,460 | -100.0% |
| CUE | -22,483 | -79.9% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
26
(0.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|